Combination Treatment May Improve Efficacy of Blood Cancer Treatment
The combination of BET-inhibitors and immune-based treatments could provide more potent treatments for blood cancers, according to a study published in Cell Reports.
BET-inhibitors are a relatively new class of epigenetic drugs designed to switch off cancer-causing genes expressed within tumor cells.
Although international clinical trials examining the use of BET-inhibitors for the treatment of blood cancers are currently underway, research has focused on the direct effects of the drugs in inducing cancer cell apoptosis, and understanding how resistance develops.
In the current study, investigators demonstrated the potential of combining epigenetic and immune-based treatments.